Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
Suresh S. Ramalingam(Emory University), Claude El Kouri(Université de Montpellier), Alex Y. Chang(Cornell University), Terezie Janaskova(Asklepios Fachkliniken München-Gauting), Stephen Della‐Fiorentina(Camden and Campbelltown Hospitals), Kamil Klenha(Agennix (United States)), Rajesh Malik(Agennix (United States)), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), J Musil(Agennix (United States)), C. Chouaïd(Université de Montpellier), Roland Schött, Giuseppe Giaccone(Cornell University), Jitka Jakesova(Agennix (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Antoaneta Tomova, Randeep Sangha, Tatyana Koynova, Jeffrey Crawford(Duke Medical Center), Miloslav Ambruš, H. Léna(Inserm), Vera Hirsh(Taipei Veterans General Hospital), Jean-Yves Douillard(European Society for Medical Oncology), Jaromı́r Roubec(Asklepios Fachkliniken München-Gauting), Valentina Tzekova(Ghent University Hospital), Julien Mazières(Université Toulouse III - Paul Sabatier), Félix Couture, Jaafar Bennouna-Louridi(Agennix (United States)), Y. Wang(Agennix (United States)), J Vaňásek(Agennix (United States)), K. Pittman(Queen Elizabeth Hospital), H. Vallerand, N.M. Ivanova, Philippe Pultar(Department of Pharmaceuticals), Stephen Begbie(Chinese University of Hong Kong), Petar Petrov(Agennix (United States)), Ronald L. Burkes(Mount Sinai Hospital), Fabrice Barlési(Hôpital Nord), Petr Zatloukal(Heidelberg University), Jing Zhu(Agennix (United States)), Y. Martinet, D. Spaëth(Centre Hospitalier Universitaire de Nantes), J. Novotny(Agennix (United States)), G. Robinet(Centre Hospitalier Régional Universitaire de Brest), Román Pérez-Soler(Cancer Clinic), Nicholas Thatcher(The Christie NHS Foundation Trust), C. Manegold(University Medical Centre Mannheim), Joshua Dass(Agennix (United States)), P.-J. Souquet, Ross Jennens
Cited by 57
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k